Felis ISSN 2398-2950

Hepatic encephalopathy

Contributor(s): Penny Watson, Agnes Delauche, Laurent Garosi

Introduction

  • Cause: underlying disorders eg congenital portosystemic shunts (PSS) Congenital portosystemic shunt (CPSS), urea cycle enzyme deficiencies or acquired PSS secondary to other hepatic disease.
  • Signs: alteration in behavior, eg head pressing, disorientation, seizures, ataxia, depression and collapse +/- gastrointestinal signs, weight loss.
  • Episodes may be related to feeding.
  • Hypersalivation  Ptyalism in a kitten with a portosystemic shunt is a common manifestation in cats.
  • Diagnosis: signs and biochemical assays.
  • Treatment: reduction in ammonia and mercapten production; antibiotics and reduced protein diet.
  • Emergency if in hepatic coma.
  • Prognosis: acute crisis can often be managed; long term prognosis depends on cause of liver dysfunction.

Pathogenesis

Etiology

Congenital portosystemic shunts

  • Venous malformations connecting the portal and systemic circulations permitting portal blood to circumvent the liver.
  • May be intra- or extrahepatic Congenital portosystemic shunt (CPSS):
    • Portocaval shunts.
    • Portoazygous shunts.
    • Persistent ductus venosus (less common).
  • Blood is diverted away from the liver thus preventing toxins from being metabolized.

Acquired portosystemic shunts

  • Secondary to chronic hepatic disease: end-stage hepatic fibrosis leads to increased resistance to intrahepatic blood flow causing collateral circulation pathways to develop which bypass the liver.
    Acquired shunts are very rare in cats.

Predisposing factors

General

Pathophysiology

  • Portal blood bypassing liver (congenital shunts) and/or hepatic dysfunction   →   toxins accumulating in the blood   →   neurological deficits.
  • Toxins implicated include:
    • Ammonia.
    • GABA/benzodiazepine.
    • Glutamate.
    • Methionine.
    • Reduced branched chain amino acids.
    • Increased short chain fatty acids.
    • Increased aromatic amino acids.
    • Manganese.
    • TNF-alpha.
    • Reactive oxygen species/reactive nitrogen species.
  • There are several theories as to the pathogenesis of hepatic encephalopathy and origin is probably multifactorial.
  • Excess [blood ammonia ] produced by action of gut bacteria on dietary protein is probably important but still controversial since the degree of correlation between hepatic encephalopathy severity and blood ammonia concentration is variable. Ammonium ions are detoxified predominantly in the liver via the urea cycle, with resultant production of glutamine. In liver failure, hepatic ammonia detoxification is ineffective, leading to hyperammonemia. The brain lacks a urea cycle and relies on production of glutamine for detoxification of ammonia, wnhich is a direct neurotoxin acting via chloride channel inhibition. 
  • Hepatic dysfunction   →   changes in the circulating amino acid composition - decrease in the concentration of branch chain amino acids and increase in the concentration of aromatic amino acids.
  • Branch chain amino acids are required for the production of excitatory neurotransmitters, levels of which decrease.
  • Aromatic amino acids are metabolized to produce 'false' neurotransmitters, which increase in concentration, thus causing the neurological signs.
  • Manganese is excreted via the hepatobiliary route and its concentration increases in liver disease. Patients with chronic liver disease and hepatic encephalopathy have increased brain manganese concentration, although whether this is causative or coincidental is unknown. Manganese-induced neurotoxicity causes astrocyte dysfunction, neuronal loss and gliosis.
  • Increases in brain glutamate (an excitatory neurotransmitter).
  • Increased cerebral concentration of an endogenous benzodiazepine-like substance. The GABAergic theory suggests hepatic encephalopathy is due to increased circulating levels of GABA derived from the gastrointestinal tract, although the theory has been modified to include the involvement of endogenous benzodiazepines, which are also increased in hepatic encephalopathy patients.
  • Circulating levels of tumor necrosis factor-a (THF-a), a proinflammatory cytokine are increased in liver failure patients and appear to correlate with HE severity. In liver failure, TNF-a production increases whilst TNF-a clearance may be reduced. Pathological derangements of the brain in HE may be induced in part by TNF-a excess. The TNF-a hypothesis links a nmber of the other hypotheses together. TNF-a increases CNS endothelial ammonia diffusion, enhances glutamate receptor-mediated neurotoxicity and is associated with significantly increased levels of GABA. Additionally, THF-a increases peripheral type benzodiazepine receptors and excess manganese potentiates in vitro production of TNF-a.

Diagnosis

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Treatment

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Outcomes

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Cabassu J, Seim H B 3rd, MacPhail C M et al (2011) Outcomes of cats undergoing surgical attenuation of congenital extrahepatic portosystemic shunts through cellophane banding: 9 cases (2000-2007). JAVMA 238 (1), 89-93 PubMed.
  • Ruland K, Fischer A, Hartmann K (2010) Sensitivity and specificity of fasting ammonia and serum bile acids in the diagnosis of portosystemic shunts in dogs and cats. Vet Clin Pathol 39 (1), 57-64 PubMed.
  • Lipscomb V J, Lee K C, Lamb C R et al (2009) Association of mesenteric portovenographic findings with outcome in cats receiving surgical treatment for single congenital portosystemic shunts. JAVMA 234 (2), 221-228 PubMed.
  • Lipscomb V J, Jones H J, Brockman D J (2007) Complications and long-term outcomes of the ligation of congenital portosystemic shunts in 49 cats. Vet Rec 160 (14), 465-470 PubMed.
  • d'Anjou M A, Penninck D, Cornejo L et al (2004) Ultrasonographic diagnosis of portosystemic shunting in dogs and cats. Vet Radiol Ultrasound 45 (5), 424-437 PubMed.
  • Watson P J (1997) Decision making in the management of portosystemic shunts. In Practice 19 (3), 106-120 VetMedResource.
  • Maddison J E (1992) Hepatic encephalopathy. Current concepts of the pathogenesis.​ JVIM (6), 341-353 PubMed.

Other sources of information

  • Tobias K M (2003) Portosystemic shunts and other hepatic vascular anomalies .In: Textbook of Small Animal Surgery. 3rd edn, Slatter D (ed), Philadelphia, p 727.
  • Maddison J E (1994) Hepatic encephalopthy in dogs and cats. Veterinary International 6, 37-43.
  • Levy J K, Bunch S E and Komtebedde J (1995) Feline Portosystemic vascular shunts. In: Kirks Current Veterinary Therapy XII W. B. Saunders pp743-749.
  • Taboada J and Dimski D S (1995) Hepatic encephalopathy; clinical signs, pathogenesis and treatment.Veterinary Clinics of North America25, 337-355.


ADDED